Novo Nordisk CEO agrees to appear at a Senate hearing to defend the ... had requested that Jørgensen not be the only industry representative in the GLP-1 agonist market to testify at the ...

In a Senate hearing, the head of Novo Nordisk argued that higher prices were needed to ensure broader access to the drugs but committed to meeting with middlemen. IE 11 is not supported.

Novo Nordisk's top executive faced a Senate grilling over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic. The Danish drugmaker's CEO, Lars Fruergaard ...

Novo Nordisk CEO Jorgensen agrees to testify before Senate over U.S. pricing of semaglutide products Ozempic is currently covered by 99% of commercial insurance plans, plus Medicare and Medicaid ...

Sept. 24 (UPI) --The CEO of Novo Nordisk is on Capitol Hill Tuesday to testify before a Senate committee about the high costs of its drugs Ozempic and Wegovy.Chairman Sen. Bernie Sanders, I-Vt ...

The CEO of Novo Nordisk plans to blame drug middlemen for the high cost of popular diabetes and weight loss drugs Ozempic and Wegovy during a Senate hearing Wednesday.

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual agreement." Latest U.S.

“During his eight-year tenure as CEO, Novo Nordisk’s sales, profits and share price have almost tripled,” Novo Nordisk said. The 58-year-old Danish executive has spent his entire career at ...

Reuters. FILE PHOTO: CEO of Novo Nordisk Lars Fruergaard Jorgensen is seen during the 6th edition of the "Choose France" Summit at the Chateau de Versailles, outside Paris on May 15, 2023.

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, to step down as company seeks a turnaround. Company found success with Wegovy and Ozempic, but share price has fallen by half in past year.

Ozempic maker Novo Nordisk NOVO.B-0.35%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...

Novo Nordisk's top executive faced a Senate grilling over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic. The Danish drugmaker's CEO, Lars Fruergaard ...